White House Reticent On Drug Pricing Regulatory Plan With Legislative Efforts In Motion
HHS plan to be publicly released in coming weeks, White House official says. Meanwhile the US House passed a resolution clearing the way for consideration of a second infrastructure package that could include major drug pricing reforms such as Medicare price negotiation as cost offsets.
You may also be interested in...
The Rebate Rule: US Pricing Proposal Becomes Congressional Piggy Bank
A policy eliminating rebates in the Medicare Part D program will be delayed until Jan. 1, 2026 – and is very likely to be repealed altogether. If that staves off more draconian reforms, the biopharma industry will celebrate.
Biden Pitches Medicare Price Negotiations That Acknowledge R&D Costs, Allow ‘Significant’ Profits
The US president’s remarks appear aimed at drawing more support for the negotiation policy. But critics are likely to be skeptical about whether such a process could result in a “fair” price.
Drug Pricing Reforms To Underwrite Major Part Of Senate ‘Soft’ Infrastructure Legislation
Senate Finance Committee directed to provide ‘nearly all’ of the spending offsets for the $3.5tn package; Committee chair Ron Wyden is focused on authorizing the US government to directly negotiate drug prices in Medicare.